GLP-1 Eligibility Checker
Estimate which GLP-1 medications you likely qualify for under FDA labeling, based on BMI, age, and comorbidities. Informational only — final decisions belong to your prescriber.
What This Checker Estimates
The GLP-1 Eligibility Checker compares your BMI, age, and comorbidities against current FDA labeling for Wegovy, Zepbound, Saxenda, Ozempic, and Mounjaro. Wegovy and Zepbound require BMI ≥30, or ≥27 with at least one weight-related condition. Zepbound was expanded in 2024 to treat moderate-to-severe obstructive sleep apnea in adults with obesity. Ozempic and Mounjaro carry an FDA-labeled indication only for type 2 diabetes — though the molecules (semaglutide, tirzepatide) are the same as Wegovy and Zepbound for weight management.
Who Is This For?
Anyone trying to understand whether they are likely to qualify for a GLP-1 prescription before talking to a prescriber. The result is informational — your real eligibility depends on your full medical history, insurance plan rules, and your prescriber's clinical judgment.
Frequently Asked Questions
What BMI qualifies for Wegovy or Zepbound?
FDA labeling requires BMI ≥30, OR BMI ≥27 with at least one weight-related condition (e.g., type 2 diabetes, hypertension, high cholesterol, OSA).
Can I get Ozempic or Mounjaro just for weight loss?
Ozempic and Mounjaro are FDA-approved for type 2 diabetes only. Their semaglutide/tirzepatide molecules are also sold as Wegovy and Zepbound for weight management. Off-label prescribing exists but coverage and access vary widely.
Does sleep apnea make me eligible for Zepbound?
Yes. In late 2024 the FDA expanded Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity (BMI ≥30).
What if my BMI is just under 30?
BMI 27–29.9 plus at least one weight-related condition meets FDA labeling for Wegovy and Zepbound. Without a comorbidity, you generally do not meet labeled criteria.
Does insurance follow FDA labeling?
Not always. Many commercial plans require additional documentation (prior authorization, lifestyle attempts) or restrict GLP-1s to type 2 diabetes. Medicare does not cover GLP-1s for weight loss as of 2026.
Related Reading
Save your result
Email yourself a copy and join the weekly Gila newsletter — actionable GLP-1 research, no spam.
These tools are for informational purposes only and do not constitute medical advice. Always consult your healthcare provider.
Ready to start your GLP-1 journey?
Gila helps you build lasting habits, understand your body, and stay on track. Join the pilot for free.
Join the Pilot